McDonald’s Corporation (NYSE:MCD) is adapting its menu as a growing number of Americans taking GLP-1 weight-loss drugs, such as Ozempic and Wegovy, modify portion sizes, snacking habits and beverage choices.
During an earnings conference call on Wednesday, CEO Chris Kempczinski He said McDonald’s is testing menu items to appeal to customers who take GLP-1 medications.
“As adoption grows, we know consumer behavior changes,” Kempczinski said.
He noted that these customers tend to prefer protein-rich meals.
Don’t miss:
vice president Jill McDonald highlighted the high-protein options already on the menu, including Snack Wraps, Sausage Biscuit Sandwiches, and McCrispy Strips.
“We’re also seeing changes around maybe less snacking, changes in some of the beverages they drink, less sugary drinks,” Kempczinski added.
Jill McDonald confirmed that the company has longer-term plans to serve this customer segment, but did not provide further details.
Adoption of the drug GLP-1 in the U.S. has steadily increased, with an estimated 10% of the population using these medications, which suppress appetite and reduce food intake.
Trending: No wonder Jeff Bezos owns more than $250 million in art – this alternative asset has outperformed the S&P 500 since 1995, delivering an average annual return of 11.4%. This is how everyday investors are getting started.
The trend is prompting companies in the food industry to adapt.
Conagra Brands and General Mills offer smaller portion options labeled “GLP-1 Compliant,” while Shake Shack introduced its “Good Fit Menu” that offers protein-rich, lettuce-wrapped burger options.
Earlier this week, McDonald’s reported strong fourth-quarter 2025 results, beating analyst expectations with revenue of $6.83 billion and earnings per share of $3.05.
The company’s $5 meal deal helped boost U.S. comparable sales by 9%, appealing to budget-conscious consumers amid rising grocery costs.
See also: From Moxy hotels to $12 billion in real estate: The company behind New York’s trendiest properties is letting in individual investors.
Last year, McDonald’s shares rose nearly 5% in a month, boosted by the $5 meal deal, which boosted U.S. comparable sales by 9% as consumers sought affordable options amid rising grocery costs.